rtPA

DRUG2 trials

Sponsors

General Hospital of Shenyang Military Region, Hui-Sheng Chen

Conditions

Ischemic StrokeStroke, Ischemic

Phase 4

Butyphthalide in Combination With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke

CompletedNCT03394950

Hui-Sheng ChenStroke, Ischemic

Start: 2018-05-25End: 2021-05-29Updated: 2021-06-02

Unknown Phase

Intravenous Thrombolysis Registry for Chinese Ischemic Stroke Within 4.5 h Onset

CompletedNCT02854592

General Hospital of Shenyang Military RegionIschemic Stroke

Start: 2017-04-01End: 2019-10-30Updated: 2019-12-17

Related Papers

Association of serum biomarkers with early neurologic improvement after intravenous thrombolysis in ischemic stroke

PLoS ONE2022-10-318 citations

Intravenous thrombolysis with 0.65 mg/kg r-tPA may be optimal for Chinese mild-to-moderate stroke.

2022-09-202 citations

Change of Serum Biomarkers to Post-Thrombolytic Symptomatic Intracranial Hemorrhage in Stroke

Frontiers in Neurology2022-06-029 citations

Early neurological deterioration after intravenous thrombolysis of anterior vs posterior circulation stroke: a secondary analysis of INTRECIS.

2022-02-2417 citations

Effectiveness of intravenous r-tPA versus UK for acute ischaemic stroke: a nationwide prospective Chinese registry study

Stroke and Vascular Neurology2021-04-2630 citations